Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polatuzumab vedotin + rituximab + dexamethasone for elderly frail newly diagnosed diffuse large B-cell lymphoma
ChiCTR2400092977Phase 2Not yet recruiting
- Sponsor
- Beijing Hospital
- Start
- Nov 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of polatuzumab vedotin in diffuse large B-cell lymphoma (DLBCL), sponsored by Beijing Hospital. Primary endpoint: Overall response rate. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
polatuzumab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2400092977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092977.